REDAELLI, SARA
 Distribuzione geografica
Continente #
NA - Nord America 5.316
EU - Europa 2.717
AS - Asia 1.053
Continente sconosciuto - Info sul continente non disponibili 9
SA - Sud America 7
AF - Africa 4
OC - Oceania 2
Totale 9.108
Nazione #
US - Stati Uniti d'America 5.231
DE - Germania 625
IT - Italia 527
CN - Cina 411
SG - Singapore 403
IE - Irlanda 374
SE - Svezia 370
UA - Ucraina 222
RU - Federazione Russa 211
GB - Regno Unito 143
CA - Canada 84
HK - Hong Kong 76
FI - Finlandia 68
IN - India 46
FR - Francia 45
VN - Vietnam 43
BE - Belgio 34
TR - Turchia 27
DK - Danimarca 26
ID - Indonesia 23
NL - Olanda 18
PL - Polonia 16
AT - Austria 14
EU - Europa 9
IR - Iran 9
KR - Corea 7
BG - Bulgaria 5
CZ - Repubblica Ceca 5
BR - Brasile 4
ES - Italia 4
CL - Cile 2
EG - Egitto 2
LT - Lituania 2
AM - Armenia 1
AR - Argentina 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
CH - Svizzera 1
JP - Giappone 1
LU - Lussemburgo 1
MK - Macedonia 1
MU - Mauritius 1
MX - Messico 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
TH - Thailandia 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 9.108
Città #
Ann Arbor 1.126
Woodbridge 589
Fairfield 455
Chandler 372
Dublin 362
Frankfurt am Main 346
Singapore 317
Houston 298
Ashburn 271
Wilmington 257
Dearborn 235
Milan 227
Jacksonville 225
Seattle 183
Cambridge 137
New York 129
Princeton 101
Santa Clara 98
Göttingen 75
Hong Kong 75
Shanghai 73
Nanjing 72
Altamura 49
Lawrence 42
Lachine 37
Beijing 34
Brussels 34
Munich 27
Boardman 26
Dong Ket 26
Nanchang 26
Fremont 25
Fürstenwalde 25
Shenyang 24
Helsinki 23
Jakarta 23
San Diego 23
Guangzhou 20
Andover 18
Ottawa 18
Tianjin 17
Falls Church 16
Jiaxing 15
Lodz 15
Toronto 15
Hangzhou 14
Jinan 14
London 14
Los Angeles 14
Kocaeli 13
Lissone 13
Romola 13
Vienna 13
Changsha 12
Hebei 12
Hefei 11
Monza 11
Norwalk 11
Pavia 11
Huizen 10
Kunming 10
Pune 10
Edmonton 9
Nürnberg 8
Rome 8
Bonndorf 7
Kiev 7
Moscow 7
Ningbo 7
Cinisello Balsamo 6
Espoo 6
Kilburn 6
Mountain View 6
Zhengzhou 6
Desio 5
Meda 5
Mumbai 5
Zanjan 5
Carate Brianza 4
Chicago 4
Daejeon 4
Hounslow 4
Philadelphia 4
Plovdiv 4
Redmond 4
San Mateo 4
Auburn Hills 3
Birmingham 3
Ceret 3
Cesena 3
Clifton 3
Dallas 3
Dottingen 3
Fuzhou 3
Haikou 3
Olomouc 3
San Francisco 3
Serio 3
St Petersburg 3
Taizhou 3
Totale 6.984
Nome #
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways 406
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 358
Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study 308
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 266
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub 265
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 245
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells 240
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 226
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 222
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 210
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma 207
Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia 205
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia 204
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases 204
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 203
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 201
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 200
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 192
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 190
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 189
Inhibition of RET tyrosine kinase by SU5416 188
Reply to P. Laneuville et al 188
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 187
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 181
Expression, purification, and inhibition of human RET tyrosine kinase 180
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants 180
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 170
Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia 167
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 166
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery 163
Dual kinase targeting in leukemia 163
Identification of a Novel Splicing Mutation in Blast Crisis Transformation of Chronic Myeloid Leukemia Integrating Whole-exome and RNA-Seq data 161
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 157
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 154
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 151
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib 146
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 146
ETNK1 is an early event and SETBP1 a late event in atypical Chronic Myeloid Leukemia 142
Novel targeted therapeutics for MEN2 140
BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients 135
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants 135
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 132
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic 131
Volatile Sedation for Acute Respiratory Distress Syndrome Patients on Venovenous Extracorporeal Membrane Oxygenation and Ultraprotective Ventilation 122
Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein 121
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBa mediated p53 nuclear exclusion 119
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 116
Clonal evolution analysis identifies ETNK1 as an early event and SETBP1 as a late event in atypical Chronic Myeloid Leukemia 114
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 110
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform InfraRed microspectroscopy and unsupervised Hierarchical Cluster Analysis. 108
Idiopathic erythrocytosis: a germline disease? 95
Clinical and Molecular features of the patients with Idiopathic Erythrocytosis 64
Paired Exome Sequencing Reveals Recurrent Germline Variants in Patients with Idiopathic Erythrocytosis 60
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 40
Totale 9.473
Categoria #
all - tutte 29.995
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.995


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.023 0 0 0 0 0 215 282 119 159 111 96 41
2020/20211.352 58 73 116 134 118 152 107 126 126 137 103 102
2021/2022755 53 77 83 47 51 70 38 34 37 81 64 120
2022/20231.491 169 461 145 151 93 197 18 81 84 23 33 36
2023/20241.066 28 34 43 60 139 299 217 38 54 23 15 116
2024/2025915 141 224 153 129 203 65 0 0 0 0 0 0
Totale 9.473